摘要
目的:观察阿奇霉素联合布地奈德雾化吸入治疗小儿肺炎支原体肺炎的临床疗效。方法:选取2018年1月～2019年1月收治的90例肺炎支原体肺炎患儿为研究对象,随机分为观察组和对照组,各45例。对照组给予阿奇霉素治疗,观察组给予阿奇霉素联合布地奈德雾化吸入治疗。结果:与对照组比较,观察组的咳嗽缓解、发热消退、啰音消失及胸部X线恢复正常的时间均明显缩短,两组比较差异有统计学意义(P<0.01)。观察组的总有效率为91.11%,明显高于对照组的总有效率75.56%,两组比较差异有统计学意义(P<0.05)。观察组的不良反应发生率为6.67%,对照组的不良反应发生率为13.33%,两组比较差异无统计学意义(P>0.05)。结论:阿奇霉素联合布地奈德雾化吸入治疗小儿肺炎支原体肺炎安全、有效,值得临床推广应用。
Objective To observe the clinical efficacy of azithromycin combined with budesonide aerosol inhalation in the treatment of children with mycoplasma pneumoniae pneumonia.Results A total of 90 children with mycoplasma pneumoniae pneumonia admitted to our hospital from January 2018 to January 2019 were selected as the research object,and they were randomly divided into observation group and control group,45 cases in each group.The control group received azithromycin treatment,and the observation group received azithromycin combined with budesonide aerosol inhalation.Results Compared with the control group,the cough relief,fever elimination,the disappearance time of pulmonary rales and the time to recovery of chest radiograph in the observation group were significantly shortened(P<0.01).The total effective rate of the observation group was 91.11%,which was significantly higher than that of the control group(75.56%)(P<0.05).The incidence of adverse reactions was 6.67%in the observation group and 13.33%in the control group,there was no significant difference between the two groups(P>0.05).Conclusion Azithromycin combined with budesonide inhalation for the treatment of children with mycoplasmal pneumoniae pneumonia is safe and effective,which is worthy of clinical application.
作者
何诗华
欧宝莲
HE Shi-hua;OU Bao-lia(Minzhong Hospital of Zhongshan City,hongshan 528441,China)
出处
《吉林医学》
CAS
2019年第4期765-767,共3页
Jilin Medical Journal
关键词
阿奇霉素
布地奈德
雾化吸入
小儿支原体肺炎
Azithromycin
Budesonide
Aerosol inhalationa
Children with mycoplasma pneumonia
